bitFlyer Makes Cryptocurrency Trading Even Easier with Launch of bitFlyer App
Today, leading cryptocurrency exchange bitFlyer has announced the launch of the bitFlyer app across Europe and the USA. The app, available for free on both iOS and Android, will allow users to buy and sell Bitcoin (BTC), Ethereum (ETH), Litecoin (LTC), Bitcoin Cash (BCH), Ethereum Classic (ETC), Monacoin (MONA) and Lisk (LSK).1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191020005009/en/
bitFlyer app iOS
The bitFlyer app will make it even easier for users to buy and sell, whilst still adhering to the same robust KYC and verification standards as the bitFlyer website.
Since 2014, bitFlyer has been trusted by millions across the globe as the most secure platform to easily buy and sell cryptocurrencies, and remains the only exchange licensed to operate across the US, Japan and Europe combined. This app launch is the latest development in a major growth strategy by the European and US businesses, to match what is already available to millions of bitFlyer Japan customers, where bitFlyer is recognised as a household name and one of the longest-standing cryptocurrency exchanges.
Yuzo Kano, bitFlyer founder and CEO of bitFlyer USA, said: “With the new bitFlyer apps, we are bringing the reliability, security and experience of Japan's market leader to our European and American customers, closing the gap between our service offerings and creating a truly global and regulated exchange product.”
Andy Bryant, Co-head and COO at bitFlyer Europe, said: “With our Buy/Sell platform, we strived to create a simpler, faster and even more transparent experience where everyone can buy cryptocurrencies in just a few minutes and from a reputable source. Now with the bitFlyer app, this is even more convenient for users.
We are staying true to our mission of making the world simpler with blockchain, by making the transparency, security and simplicity of our robust trading platforms available via a quick, single app download.”
Buy instantly and securely
The bitFlyer app was created with users in mind, making it even easier for those who prefer navigating from a smartphone to buy and sell cryptocurrencies. Current bitFlyer users can log on to the app with their existing account details, while new traders can register by using an email address, and inputting the relevant information for KYC procedures to deposit and begin trading.
Other features of the bitFlyer app include:
● Users are shown real-time price data, notified about the latest market movements and given access to the latest cryptocurrency news without leaving the app, encouraging users to always stay on top of the market and make informed decisions
● Users can clearly follow their position, making it even easier to keep track of profit and loss (PnL), view trade history and seamlessly visualise their portfolio
● Users can now simply scan a QR code to send and receive virtual currencies with bitFlyer
● From October 21st to October 27th, new customers downloading the bitFlyer app and registering a new verified account will receive €10 (or $10 if based in the US) in BTC without any deposit required.
Key features:
● Buy Bitcoin, Ethereum, Litecoin and more in just a few taps using USD, EUR, or JPY 2
● See real-time price data and get notified about market movements
● Added news functionality allows users to access the latest industry news without leaving the app
bitFlyer launched in the USA in November 2017, followed by bitFlyer Europe in January 2018, both as fully owned subsidiaries of bitFlyer, Inc., a household name in the cryptocurrency space in Japan and one of the longest-standing cryptocurrency exchanges. It is the only cryptocurrency exchange to be licenced in Japan, the US and Europe combined, and has also recently been recognised as one of only 10 exchanges that isn’t faking trading volumes.
bitFlyer is passionate about the future of the cryptocurrency industry and aims to support that future by setting the global standard for exchanges. It believes that standards and regulations are fundamental to the future of the industry and is often involved in conversations at the highest level, including having taken part in the recent G20 discussions. It was also involved in the amendment to the Payments Act in Japan which famously recognised bitcoin as legal tender.
The company continues to build out its product portfolio in line with its vision to break down barriers of entry that many face while accessing cryptocurrency. bitFlyer Japan already offers a wide range of products, and the addition of new Apps in the US and EU is the beginning of the brand’s ambition to expand access to cryptocurrency on a global scale.
ENDS
About bitFlyer EUROPE S.A.
bitFlyer EUROPE S.A. is a wholly-owned subsidiary of bitFlyer, Inc., a leading bitcoin and blockchain company based in Japan. The European office is located in Luxembourg and operates an exchange platform for European traders to buy and sell cryptocurrencies. bitFlyer EUROPE S.A. site: https://bitflyer.com/en-eu/
About bitFlyer USA, Inc.
bitFlyer USA, Inc. is a wholly-owned subsidiary of bitFlyer, Inc., a leading Bitcoin and blockchain company based in Japan. The US office is located in San Francisco and operates an exchange platform for US traders to buy and sell cryptocurrencies. Launching in the U.S. in 2017, bitFlyer USA currently operates in 46 states and territories, including New York as a holder of the New York Bitlicense. bitFlyer USA, Inc., site: https://bitflyer.com/en-us/
1MONA and LSK available in Europe and Japan only.
2 Depending on jurisdiction
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191020005009/en/
Contact information
Lauren Armour
Tyto PR
07826 557 326
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom